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Purpose: The purpose of this study was to assess the short-term and mid-term results of endovascular aneurysm repair
with the Zenith stent graft (J Vasc Surg 2002;36:217-25.) in a single-center prospective study.
Method: Between October 1998 and July 2001, we used the Zenith stent graft for elective endovascular aneurysm repair
in 116 patients, six of whom were women. The mean age was 75 years, and the mean aneurysm diameter was 60.3  8.8
mm. Stent grafts were oversized 10% to 20% relative to computed tomographic (CT) scan–based diameter measurements.
All repairs were performed in the operating room through surgically exposed femoral arteries. The results were assessed
before discharge with three-phase, contrast-enhanced CT scan and plain abdominal radiograph. These studies were
repeated at 1, 6, 12, and 24 months after operation. Follow-up periods ranged from 1 to 34 months.
Results: No failed insertions and no conversions to open surgery occurred. The diameter of the main body of the stent
graft was 28 mm or more in 73 patients (63%). Additional stents were inserted during surgery to treat kinking in eight
patients (6.9%) and renal artery encroachment in two patients (1.7%). Mean fluoroscopy time was 35.1  18.3 minutes,
contrast load was 146 53 mL (350 mg/mL), and estimated blood loss was 249 407 mL. The major complication rate
was 9.5%, and the minor complication rate was 10.3%. The perioperative complications were myocardial infarction in four
patients, arrythmia in four patients, and pulmonary embolism, renal failure, stroke, small bowel obstruction, femoral
stenosis, digital embolism, and graft limb thrombosis in one patient each. All 116 patients went home from the hospital,
but one patient died 2 weeks later of a combination of pulmonary embolism and myocardial infarction. Endoleak was seen
on the first CT scan in 16 patients (15%); 15 were type II, and one was type III. No endoleaks of type I or IV were seen.
Additional interventions were performed for each of the following conditions: type II endoleak (n 4), type III endoleak
(n  1), femoral clamp injury (n  1), renal artery stenosis (n  1), and graft limb occlusion (n  1). One patient had
acute aneurysm dilatation and rupture caused by a type II endoleak through the inferior mesenteric artery 6 months after
stent graft implantation. No cases were seen of late graft occlusion, stent graft migration, stent fracture, barb fracture, or
secondary endoleak.
Conclusion: The Zenith device is safe, versatile, and effective in the short to medium term. Most patients need wide stent
grafts (>28 mm proximally and >16 mm distally) to achieve 10% to 20% oversizing to prevent type I endoleak. (J Vasc
Surg 2002;36:217-25.)
The Zenith stent graft (Cook, Inc, Bloomington, Ind)
was developed in Australia1 where it has been used in its
current form2 since 1997. This device has also been widely
used in Europe, but in the United States, its use has been
confined to Food and Drug Administration trials. We have
used the Zenith system since 1998, accumulating a total of
116 cases with follow-up beyond a month. This experience
is reported here as the basis for an evaluation of the safety,
efficacy, and design of the Zenith device.
METHODS
This study was performed under two similar protocols:
an individual physician-sponsored investigational device
exemption with 89 patients and an industry-sponsored
(Zenith, Cook, Inc) investigational device exemption with
27 patients divided into one low-risk arm and one high-risk
arm. Both protocols were approved by the University’s
human studies review board.
Device description. The entire system has been de-
scribed previously in detail.2-4 We used the Trifab version in
this study. The name refers to the routine use of three
components—a bifurcated main body and two limbs.
The docking sites of the main body and the limbs all
have a diameter of 12 mm, but the other ends vary in
diameter according to the diameter of the implantation
sites. The proximal end of the main body has a diameter 22
to 32 mm, and the distal ends of the limbs have diameters of
8 to 24 mm. Component lengths are available in incre-
ments of 15 mm. One of the most distinctive features of the
Zenith device has an uncovered proximal stent, which
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carries nine caudally oriented barbs at four different levels
to enhance suprarenal fixation. The stents at the ends of
each component are on the inside of the graft. All other
stents are sutured to the outside. The delivery system has a
long tapered tip and a valved sheath. The sheath is 18F
(inner diameter) for main body grafts measuring 22 to 26
mm and 20F for those measuring 28 to 32 mm.
Patient selection. The basic inclusion criteria were
the same for both protocols. These criteria are listed in
Table I. The feasibility of endovascular repair was assessed
with computed tomographic (CT) scanning and catheter
angiography. Suitable patients were enrolled after full in-
formed consent in accordance with the requirements of our
institutional committee on human research.
Stent graft sizing. Preoperative measurements of
neck diameter, aneurysm diameter, and common iliac di-
ameter were made on the basis of CT scan images. Mea-
surements of neck length, aneurysm length, common iliac
artery length, external iliac artery diameter, and neck and
length angulation were made on the basis of angiography
with calibrated catheters. The proximal stent graft diameter
was oversized by 4 to 6 mm relative to the outer diameter of
the neck, as measured on the transaxial CT scan. The distal
stent graft diameter was oversized by 0 to 2 mm relative to
the largest diameter of the iliac implantation site. The main
body stent graft was selected from five available lengths to
minimize the gap between the contralateral docking site
and the contralateral iliac orifice.
Insertion procedure. The steps in this operation have
been described in detail elsewhere.4 One unusual feature of
the Zenith system is two-stage deployment of the main
body. The central portion of the main body deploys as soon
as it is released from the sheath, but the proximal stent is
constrained within its own little cap, which is pushed off
after contralateral stump catheterization. The stainless steel
Z-stents are self-expanding. Nevertheless, a large compliant
balloon is used to mold the fully deployed stent graft.
Completion angiograms are performed with all guidewires
removed so that any potential for kinking manifests itself. If
necessary, a variety of adjunctive maneuvers are used to
treat type I endoleaks, kinks, or stent graft impingement on
the renal arteries.
In the case of type I endoleaks, these maneuvers include
balloon dilation for reorientation of the proximal stent,
additional stent implantation, and additional stent graft
implantation. As a result, no patients in this series left the
operating room with a type I endoleak.
Palmaz stents (Cordis, Johnson & Johnson, Warren,
NJ) were deployed into the renal arteries in two cases to
clear a passage for blood around the top on the stent graft.
One of these cases had shown impaired renal blood flow
(Fig 1, A and B). In the other case, renal flow was brisk and
fabric encroachment was suspected on the basis of the
position of the proximal stent and graft markers.
Table I. Inclusion criteria for Zenith stent graft
1. Proximal neck
A. 10 mm in length
B. 28 mm in diameter
C. Infrarenal neck/AAA angulation 80 degrees
2. Iliac diameter 7 mm (after balloon angioplasty if necessary)
3. Dispensable IMA
4. Iliac artery angulation 90 degrees or 60 degrees in
presence of severe calcification
5. Both iliac implantation sites 2 cm in length, 16 mm in
diameter
6. No pregnancy
7. No anaphylactic reaction to contrast material
8. No allergy to stainless steel or polyester
9. Willingness and ability to comply with follow-up schedule
10. No serious systemic or groin infection
11. No coagulopathy
Fig 1. A, Intraoperative angiogram showing occlusion of the left
renal artery. B, Intraoperative angiogram through a brachial guid-
ing catheter, showing beneficial effect of a Palmaz stent (arrows) in
the orifice of the left renal artery.
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Wallstents (Boston Scientific, Minneapolis, Minn) were
used in eight patients to treat kinking or compression or
anticipated compression of the graft limbs at points of acute
angulation (Fig 2, A, B, and C). Palmaz stents were used in
two cases to support the graft limbs where they passed
through areas of calcification and narrowing in the distal
aorta (Fig 3, A, B, and C).
In two instances, the Zenith bifurcated system was
converted to an aortouniiliac graft through the implanta-
tion of a tapered stent graft from the main body to the
ipsilateral docking site. In one of the cases, uniiliac conver-
sion was used to divert blood away from a heavily calcified
fragile external iliac artery as the only way to achieve hemo-
static repair. In the other case, the contralateral limb had
never been catheterized and the limb had been deployed
between the contralateral iliac artery and the aneurysm sac
outside the main body of the stent graft. On both occa-
sions, conversion, contralateral iliac occlusion, and femo-
ral-femoral crossover were accomplished without further
complications.
Follow-up. Routine follow-up included three-phase
contrast-enhanced CT scans before discharge and at 1, 6,
Fig 2. A, Preoperative angiogram showing tortuosity of both common iliac arteries, particularly the left. B, Intraop-
erative angiogram after Wallstent placement, showing the smoothly curved course and wide patency of the left limb. C,
Postoperative abdominal radiograph showing the Wallstent in the left limb of the graft.
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and 12 months and annually thereafter. The details of CT
scan data acquisition and processing have been described in
a previous report.2 Posteroanterior and lateral abdominal
radiographs were performed on the same schedule as CT
scanning to assess stent graft structural integrity, shape, and
position. Patients were seen in clinic at 2 weeks after surgery
and then at 1, 6, and 12 months and annually.
Treatment of endoleak. Type II endoleaks on com-
pletion angiography were observed. Type I and type III
endoleaks noted on completion angiography were treated
immediately as described previously. Our policy was to
investigate proximal type I endoleaks or possible type I
endoleaks that were seen on the initial CT scan angio-
graphically, although no such cases were seen in this study.
All other endoleaks were observed. Those that persisted to
1 month were managed according to their presumed type,
which depended mainly on the size and location of the
perfused area. Isolated posterior endoleaks were presumed
to be lumbar to lumbar only and were observed. All others
were investigated angiographically with a view to coil em-
bolization of inferior mesenteric feeders. According to our
policy, aneurysm enlargement of more than 5 mm (not
seen in this series) was also an indication for angiography
and treatment.
Data collection. Routine prospective data collection
included information on patient characteristics, preopera-
tive arterial anatomy, preoperative and postoperative inter-
ventions, postoperative changes in aneurysm diameter, and
the presence or absence of an endoleak.
RESULTS
Between October 1998 and July 2001, we performed
endovascular repair of abdominal aortic aneurysm (AAA) in
116 patients with the Zenith bifurcated stent graft. Of the
patients treated, 24.5% were American Society for Anesthe-
siology (ASA) classification II, 63.4% were ASA classifica-
tion III, and 11.8% were ASA classification IV. Patient
demographics and comorbid conditions are shown in Table
II. Follow-up periods ranged from 1 to 34 months, with a
mean of 10.3 9.8 months. Fourteen patients were lost to
follow-up.
Many patients treated in this study had wide implanta-
tion sites. Proximal neck diameter was 26 mm or more in
Fig 3. A, Preoperative angiogram showing a narrow, calcified
distal aorta. B, CT of the distal aorta, showing heavy calcification.
C, CT 6 months after endovascular repair, showing the two graft
limbs within the distal aorta. Both limbs contain Palmaz stents;
hence, their D-shaped cross-sectional profile. The graft lumens are
actually larger than they appear, due to the stent artifact, and the
patient has normal femoral pulses.
Table II. Patient demographics (n  116) and
comorbid conditions
Male/female 110/6
Mean age (y) 75  7
Coronary artery disease 61.2%
Congestive heart failure 15.5%
Arrhythmia 22.4%
Chronic obstructive pulmonary disease 24.1%
Diabetes mellitus 16.4%
Hypertension 60.3%
Chronic renal failure* 12.9%
Smoking history 63.8%
Peripheral vascular disease 11.2%
No. of patients on chronic coumadin therapy 13
*Preoperative creatinine 1.5 mg/dL.
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30 patients, with a mean of 23.9 2.8 mm for the group as
a whole. Consequently, the diameter of the main body of
the stent graft was 28 mm or more in 73 patients, with a
mean of 28.2 4.2 mm for the group as a whole. Ipsilateral
common iliac diameter was 14 mm or more in 46 patients,
with a mean of 14.3  5.2 mm for the group as a whole.
Consequently, the ipsilateral limb of the stent graft was 16
mm or more in 46 patients, with a mean of 14.9 3.4 mm
in the group as a whole. Contralateral common iliac diam-
eter was 14 mm or more in 41 patients, with a mean of
13.3 3.1 mm for the group as a whole. Consequently, the
contralateral limb of the graft was 16 mm or more in 42
patients, with a mean of 14.8  3.2 mm for the group as a
whole. Many patients also had other forms of challenging
arterial anatomy (Table III). Four patients had associated
or isolated common iliac aneurysms that necessitated pre-
deployment embolization of the internal iliac artery and
implantation of the stent graft limb in the external iliac
artery.
All repairs were completed successfully. No failed inser-
tions and no conversions to open surgery were seen. Data
on the operation and perioperative recovery are shown in
Table IV. Early and late complications are shown in Table
V. All patients went home alive, although one died 2 weeks
later of a combination of autopsy-proven pulmonary em-
bolus and myocardial infarction. None of the other myo-
cardial infarctions or arrythmias had any serious effects,
except one in which myocardial infarction led to cardiac
catheterization, which was complicated by contrast-in-
duced renal impairment. One patient suffered a periopera-
tive stroke. This patient’s intraoperative course was notable
for intraoperative hypotension, resulting from a combina-
tion of severe aortic stenosis and general anesthesia. In the
immediate postoperative period, this patient’s deficits var-
ied according to blood pressure. Functional recovery was
complete within 3 months of operation. One patient had a
small bowel obstruction develop on the third postoperative
day. The cause was small bowel volvulus around an adhe-
sive band from previous surgery. Two patients had new
onset claudication in the postoperative period. In one of
these, the cause was recurrent external iliac artery tortuos-
ity, leading to kinking and thrombosis of the graft limb,
which was implanted in the external iliac artery (Fig 4, A, B,
and C). Femoral-femoral crossover graft successfully re-
stored femoral flow and relieved the symptoms. The other
case of new onset claudication was the result of clamp injury
with plaque fracture and localized dissection, which neces-
sitated a return to the operating room for endarterectomy.
Another patient had self-limited toe pain and discoloration,
which we attributed to embolism.
Endoleak was seen on the first postoperative CT scan in
16 patients (14.5%) and was still present at 1 month in 12
(11%). At 1 month, five patients had CT scan findings
suggestive of type II endoleak through the inferior mesen-
teric artery (IMA). Angiography was performed in four
cases, of which one proved to be a type III junctional
endoleak that necessitated additional stent graft placement.
The other three patients underwent successful emboliza-
tion of the IMA trunk via selective catheterization of the
superior mesenteric artery–IMA collateral route in the an-
giography suite. Two of these patients had no demonstra-
ble endoleak on CT scan performed at 6 months. The other
patient continues to show a persistent type II lumbar
endoleak at 6 months with no increase in AAA size. The
remaining endoleaks were assumed to be type II through
the lumbar arteries on the basis of CT scan findings. All
these have been observed, and all but four have since
resolved. In patients with 1-year follow-up, mean aneurysm
size decreased from 60.2  8.8 mm to 51.2  9.4 mm.
Table III. Patients with “difficult” anatomic
characteristics
No. of
patients
Infrarenal neck/AAA aneurysm angle 45 degrees 34
Infrarenal neck length 15 mm 15
Infrarenal neck diameter 26 mm 30
Circumferential thrombus at neck
(partial/complete)
19/3
RCI moderate to severe tortuosity 30
LCI moderate to severe tortuosity 30
RCI moderate to severe calcification 30
LCI moderate to severe calcification 29
RCI, Right common iliac artery; LCI, left common iliac artery.
Table IV. Perioperative data
Operating time (min) 175.0  52.7
Fluoroscopy time (min) 35.1  18.3
Contrast (mL) 146.2  53.1
Regional anesthetic (no. of patients) 100
General anesthetic (no. of patients) 16
Estimated blood loss (mL) 249  407
Time to oral intake (days) 0.46  0.50
Time to ambulation (days) 1.07  0.96
Length of stay (postoperative days) 2.9  1.1
Table V. Complications
Perioperative complication No. of patients
Arrythmia 4
Myocardial infarction 4
Pulmonary embolus* 1
Stroke 1
Renal failure (dialysis) 1
Wound hematoma 3
Wound lymphocele 4
Wound infection 1
Bowel obstruction 1
Digital embolism 1
Graft limb thrombosis 1
Femoral clamp injury 1
Late complication
Renal artery occlusion 1
Rupture 1
Endoleak necessitating
reintervention
4
*Death.
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The single case of untreated type II inferior mesenteric
endoleak deserves a special mention because the manage-
ment departed from our usual policy and because the
patient went on to rupture. This patient (mentioned previ-
ously) had contrast-induced renal impairment after cardiac
catheterization. We made no attempt to treat the endoleak
for fear of inducing further renal damage in the setting of
stable aneurysm diameter for the first 6 months of follow-
up. At 7 months, the patient suddenly developed abdomi-
nal pain with CT scan signs of aneurysm dilatation (1 cm)
and rupture. At operation, no arterial clamps were applied
before opening of the AAA sac. The only source of bleeding
into the aneurysm was the IMA, which was suture ligated.
The stent graft was left in place. On the third postoperative
day, the patient had a fatal myocardial infarction.
Two additional patients had significant renal complica-
tions. One needed dialysis in the postoperative period
because of contrast-induced exacerbation of baseline renal
dysfunction. The other was found, on CT scan, to have
right renal artery thrombosis 6 months after stent graft
implantation. On review of angiograms from the initial
operation, it was discovered that markers on the proximal
edge of the graft were at the same level as the renal arteries,
indicating impingement on the renal orifices (Fig 5, A).
The completion angiogram showed no apparent impair-
ment of renal perfusion, hence the oversight. In addition,
the completion angiogram showed a less severe degree of
impingement on the left side. Repeat angiography showed
right renal occlusion and left renal stenosis (Fig 5, B).
Because the patient had contraindications to thrombolysis,
no attempt was made to treat the occluded renal artery;
however, a stent was placed in the left renal artery to push
the proximal margin of the graft out of the renal flow
channel.
No patients have shown significant aneurysm dilatation
(2 mm from baseline). No cases of stent fracture, barb
fracture, stent graft migration, late graft limb occlusion, or
secondary endoleak were seen.
DISCUSSION
Endovascular aneurysm repair with the Zenith system
appears to be safe. Only one perioperative death and few
serious complications occurred. The procedure also appears
to be effective, at least in the short to mid term. No failed
insertions or conversions to open surgery were seen, and all
patients were free of direct endoleak (types I and III) within
a month of operation. The sole failure of therapy was a case
of aneurysm rupture caused by an untreated type II en-
doleak through the IMA. This case confirms our view that
such leaks should be treated aggressively5 but has no impli-
cations for stent graft performance.
By the time we started to use the Zenith device, we
already had a large experience with other systems of endo-
vascular aneurysm repair.4,5 The only learning curve in this
series related to specific characteristics of the Zenith device,
some of which resulted in complications that we subse-
quently learned to avoid.
Fig 4. A, Preoperative angiogram showing tortuosity of the right
external iliac artery. B, Intraoperative angiogram showing straight-
ening of the right iliac artery by the right limb of the stent graft. C,
Plain radiograph at 1 month after stent-graft insertion, showing
recurrent iliac tortuosity and kinking of the stent graft.
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For example, the case of renal artery occlusion yielded
several important lessons regarding the behavior of the
Zenith device. Although two-stage deployment of the main
body permits accurate deployment, one needs to be aware
of the relationship between the relative locations of visible
stents or markers and the proximal margin of the graft.
Sometimes a look at the angiograms in unsubtracted mode
is necessary. One also needs to be aware that covering more
than half the renal orifice without any appreciable change in
renal flow or profile is possible (Fig 5, A). Once deployed,
the main body of the stent graft cannot be moved more
than 2 to 3 mm. The only way to salvage an inadvertently
covered renal artery is renal stent placement (Fig 1).
The case of graft limb occlusion was also instructive.
The graft appeared free of kinks on completion angiograms
only because of stent graft–induced straightening, which
prevented kinking (Fig 4, A). The return of iliac coiling was
associated with delayed angulation, kinking, and occlusion
of the stent graft (Fig 4, B). We take from this that native
anatomy will reassert itself, intraoperative findings are not
permanent, and additional stent support may be warranted
in cases of severe tortuosity (Fig 2). We have become fairly
liberal with adjunctive stenting, hence the intraoperative
insertion of eight Wallstents. This approach was perhaps
responsible for the low rate of limb thrombosis (1%).
Other complications, notable by their absence, in-
cluded failed insertion, iliac injury, inadvertent internal iliac
occlusion, type I endoleak, secondary endoleak, and migra-
tion. Many of the patients in this series had severe iliac
tortuosity that was often associated with calcification. We
found that the combination of a stiff guidewire (Lunder-
quist) and the external profile of this system (long taper,
sheath size 20F) allowed transfemoral insertion in cir-
cumstances that would otherwise have necessitated invasive
adjunctive maneuvers, such as iliac straightening, iliac con-
duit, or direct iliac access.
The routine use of three independently deployed com-
ponents, two limbs and a main body, allowed us to focus on
one target at a time and achieve accurate distal placement
by varying the overlap between components. In theory, this
introduces an additional junction and another potential site
for stent graft instability. However, the potential for kink-
ing and component separation is minimized by the use of a
long main body. On the contralateral side, the gap between
the docking site and the iliac orifice is short and the poten-
tial for movement small, and on the ipsilateral side, there is
often no gap at all because the docking site is usually inside
the ipsilateral iliac artery.
The absence of type I endoleak may be attributable, in
part, to the wide range of stent graft diameters. Eurostar
data show a decline in the rate of type I endoleak as the
degree of oversizing increases to 20%.6 This degree of
oversizing is often difficult to achieve with the current Food
and Drug Administration–approved devices,7,8 for which
the largest available diameter (in the United States) is 26
mm. We used a graft smaller than 28 mm in less than half of
the cases in this series.
As far as we know, only been one case has been reported of
barb fracture with the current Zenith stent design.9 Perhaps
this phenomenon is rare, or perhaps diagnosis is just difficult
even with high resolution radiographs in multiple views.
Our follow-up period is too short to draw conclusions
regarding the incidence of migration and late rupture, but
these also seem to be rare complications, given the paucity
of reported cases and the large number of Zenith stent
grafts that have been inserted worldwide in the past 4 years.
Barb-mediated attachment seems to be important in pre-
vention of migration and late rupture, even when some of
the barbs fracture.10 Both migration and aneurysm rupture
are far more common with the AneuRx system (Medtronic,
Santa Rosa, Calif), which lacks barbs, than the Ancure system
(Guidant, Menlo Park, Calif), which (like the Zenith system)
has a self expanding Z-stent and many barbs.
Fig 5. A, Poor-quality intraoperative angiogram, showing both re-
nal arteries with a marker on the stent graft overlying the right renal
orifice. There are no apparent abnormalities of renal artery flow or
appearance. The stents and markers are barely visible on this sub-
tracted image. B, Aortogram 6 months after stent-graft implantation,
showing occlusion of the right renal artery and stent-graft impinge-
ment on the left renal orifice. The right renal artery was left untreated
and the left treated with a balloon-expanded stent.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 2 Abraham et al 223
We conclude that the Zenith device is safe, versatile,
and effective as a means of excluding AAAs from the
circulation. In another 4 years, we will have the data to
comment on its stability and its efficacy as a means of
preventing AAA rupture.
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DISCUSSION
Dr Wesley S. Moore (Los Angeles, Calif). First of all, I
would like to thank Dr Chuter for sending me a copy of his
manuscript well in advance of the meeting.
Dr Chuter and his colleagues are to be congratulated for what
can only be called a remarkable success story in the management of
patients with abdominal aortic aneurysm using a stent graft. They
have described their experience during the investigational phase of
the Zenith stent graft with implantation in 116 patients. It is
particularly noteworthy that they have had a 100% success rate in
implantation, and no patient required conversion to open repair in
their series. No other series to date of either the approved or the
investigational stent grafts has been able to accomplish that record.
In my personal experience with nearly 200 implantations using the
Ancure device, my overall success rate has been 93%. While the
recent success rate is better than the early experience, due primarily
to better patient selection, it has still not reached the 100% success
level. Dr Chuter’s success must be credited to at least two factors:
good patient selection due to his extensive experience with stent
grafts using other platforms, and the versatility as well as the
streamlined delivery system of the Zenith stent graft. It is also
noteworthy that 63% of his implants utilized proximal attachment
systems that were 28 mm. Since the currently approved devices
have a limit of 26 mm, it would appear that the Zenith system will
expand the utilization of stent grafts in patients who would not
have been candidates with other devices. Likewise, more than a
third of the patients had iliac arteries that were 14 mm in
diameter and required distal attachment systems that were 16
mm in diameter. In the case of the Ancure system, which is a
unibody construction with graft limbs being equal to half the
diameter of the proximal attachment system, the maximum diam-
eter of an iliac artery that could be accommodated would be 13
mm. Thus, once again, stent graft utilization has been expanded by
the Zenith system. Increased utilization and ability to achieve a
100% success rate for implementation is due in large part to the fact
that the delivery sheaths range from 18 to 20 French diameter. In
the case of the Ancure system, a 23 French delivery system is
required. Thus, the Zenith system is able to pass through smaller
diameter arteries. This will also have an effect of increasing utiliza-
tion. The authors’ experience is also remarkable in that they were
able to completely avoid Type I endoleaks. Their overall endoleak
rate was an acceptably low 14.5%, which dropped to 11% by 1
month. The vast majority of these were Type II with only one Type
III endoleak that was treated by secondary intervention. Their
30-day mortality rate included one patient, for a 0.86% overall
mortality, and the nonfatal myocardial infarction rate was 3.45%.
There were single instances of other complications that were not
particularly device-related with the exception of renal artery com-
promise. Here we do have a problem that is device specific. Since
the Zenith system uses a stent that extends above the renal arteries,
the placement of the covered portion of the stent in relationship to
renal artery orifices can be a problem if there is an attempt to treat
patients who have a short proximal neck. The authors report two
cases in which the fabric partially covered the renal arteries and
required secondary intervention with the placement of a Palmaz
stent to push down the fabric and maintain patency of the renal
artery. One further patient was found to have a renal artery
occlusion on one side and a partial occlusion on the other. A
Palmaz stent salvaged the stenotic artery but the renal occlusion
resulted in the loss of a kidney. Finally, there was one patient who
went on to rupture an aneurysm within 6 months of implantation.
This apparently was due to a Type II endoleak secondary to a
patent inferior mesenteric artery, which resulted in aneurysm en-
largement and rupture. The authors stated that they were reluctant
to treat this because of the fact that the patient had contrast-
induced compromised renal function, and they were worried about
making it worse. Clearly, if they had it to do over again, I suspect
that they would have intervened and accepted further compro-
mised renal function rather than accepting what turned out to be a
fatal rupture.
I have several questions that I would like to pose to the
authors.
First, they mentioned that no patient was allowed to leave the
operating room with a Type I endoleak and that there were several
options available to manage this intraoperatively. In fact, how
many Type I endoleaks did they see on the first arteriogram, or was
the 10% to 20% oversizing effective in preventing them in the first
place?
Second, were the 116 patients treated with the Zenith stent
graft consecutive, or were patients mixed and matched among
several stent graft prototypes under investigation? With a 100%
implant success rate, the issue is, were there patients who were
turned down for the Zenith stent graft who underwent implanta-
tion with another device?
Third, there has been considerable concern about stent graft
designs that involved placing struts across the renal arteries, includ-
ing the Zenith device. While it is easy to understand how compro-
mised renal function might occur if the fabric were to partially
cover the renal artery, might some of the patients with compro-
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mised renal function, attributed to contrast sensitivity, be in fact a
consequence of embolization off a strut that crosses a renal artery?
And fourth, the authors have made a very strong case for the
utility and versatility of the Zenith system. Can they share with us
any information as to how soon this device will be commercially
available?
Finally, I very much enjoyed reading the authors’ manuscript,
and recommend it to you for your consideration at the time of its
publication.
Dr Timothy A. M. Chuter. Thank you, Dr Moore, for your
insightful comments and questions. If only I had equally insightful
answers.
We lack good data on the rate of intraoperative endoleak. The
treatment of endoleak was generally regarded as just another stage
in the primary procedure. I can tell you that we added proximal
extensions in only two cases, both of which had a proximal Type I
endoleak on the initial angiogram. I am a firm believer in oversiz-
ing as a means of preventing Type I endoleak. As the Eurostar
group demonstrated, the lowest endoleak rate occurs with 20%
oversizing.
Regarding your second question, no, these were not consec-
utive cases. Our switch to Zenith took place over a 2-year period,
during which we also used a homemade stent-graft. Early in the study,
the homemade stent-graft predominated, mainly because there was a
long delay in Zenith device manufacture. More recently, we have used
the homemade stent-graft only in cases that did not meet the Zenith
selection criteria. The availability of a backup device for the very
difficult cases was probably a big factor in the high success rate
reported here. As Michael Lawrence-Brown has noted, the failure rate
with the Zenith device is very low when one sticks to the stated
selection criteria, especially those that relate to neck anatomy.
I used to be more concerned about the effects of pararenal
stent placement than I am now. It is certainly possible that a
transient shower of very small emboli was responsible for some
postoperative renal impairment, but I think contrast nephropathy
is a more important cause. There were no signs of renal infarction
on the postoperative CT and no evidence of continuing deteriora-
tion to suggest ongoing embolism. The most likely source for an
intraoperative shower of small atheroemboli would be the aorta,
but had this occurred, we would have expected to see evidence of
embolism elsewhere.
The people at Cook are in the process of submitting the results
of their multicenter study to the FDA. If, as they hope, the FDA
accepts 5-year data from Australia as evidence of long-term effi-
cacy, the device might be available in the second quarter of next
year. On the other hand, if they are required to have 1 year
follow-up from the US study, the device will not be available until
the fourth quarter.
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